GERD

GERD Statistics

  •  Gastroesophageal reflux disease (GERD) is characterized by heartburn and acid regurgitation, where there is reflux of stomach contents into the esophagus.
  •  GERD symptoms are widespread in the community and range from 2.5% to more than 25%. (Savarino et al. 2017)
  •  The history and prevalence of GERD is difficult to establish because of the lack of a standard and universally accepted definition.
  •  In North America, it is estimated that the prevalence of GERD is 15%. (Eusebi et al. 2018)
  •  GERD has detrimental societal consequences, and negatively impacts quality of life and work productivity. (Hunt e
    GERD Statistics

    Click to view full infographic on GERD

    t al. 2017)
  •  Proton pump inhibitors are one type of drug that can be used to reduce stomach acid and relieve GERD symptoms.
  •  Proton pump inhibitors are one of the most common drugs prescribed in Canada. In 2012, there were more than 11 million prescriptions dispensed nationwide. (Farrell et al. 2017)
  •  In 2017, spending on proton pump inhibitors by public drug programs totaled $198.2 million in Canada, ranking the drug seventh in terms of public drug program spending. (Canadian Institute for Health Information 2017)
  •  A Canadian study estimated that patients with GERD lose 16% of their work time due to their symptoms. (Fedorak et al. 2010)
 
Citations:
Canadian Institute for Health Information. 2017. Prescribed drug spending in Canada, 2017: A focus on public drug programs. Ottawa, ON: CIHI.https://secure.cihi.ca/free_products/pdex2017-report-en.pdf [accessed 3 September 2018]
Eusebi LH et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-40.
Farrell B et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354-64.
Fedorak RN et al. Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal reflux disease in Canada: Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010 Jul;24(7):431-4.
Hunt R et al. World Gastroenterology Organisation Global Guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017 Jul;51(6):467-78.
Savarino E et al. The natural history of gastro-esophageal reflux disease: A comprehensive review. Dis Esophagus. 2017 Feb 1;30(2):1-9.

These resources were made possible through a partnership between Medtronic and CDHF

GERD Statistics

  •  Gastroesophageal reflux disease (GERD) is characterized by heartburn and acid regurgitation, where there is reflux of stomach contents into the esophagus.
  •  GERD symptoms are widespread in the community and range from 2.5% to more than 25%. (Savarino et al. 2017)
  •  The history and prevalence of GERD is difficult to establish because of the lack of a standard and universally accepted definition.
  •  In North America, it is estimated that the prevalence of GERD is 15%. (Eusebi et al. 2018)
  •  GERD has detrimental societal consequences, and negatively impacts quality of life and work productivity. (Hunt e [caption id="attachment_2125" align="alignright" width="236"]GERD Statistics Click to view full infographic on GERD[/caption] t al. 2017)
  •  Proton pump inhibitors are one type of drug that can be used to reduce stomach acid and relieve GERD symptoms.
  •  Proton pump inhibitors are one of the most common drugs prescribed in Canada. In 2012, there were more than 11 million prescriptions dispensed nationwide. (Farrell et al. 2017)
  •  In 2017, spending on proton pump inhibitors by public drug programs totaled $198.2 million in Canada, ranking the drug seventh in terms of public drug program spending. (Canadian Institute for Health Information 2017)
  •  A Canadian study estimated that patients with GERD lose 16% of their work time due to their symptoms. (Fedorak et al. 2010)
 
Citations:
Canadian Institute for Health Information. 2017. Prescribed drug spending in Canada, 2017: A focus on public drug programs. Ottawa, ON: CIHI.https://secure.cihi.ca/free_products/pdex2017-report-en.pdf [accessed 3 September 2018]
Eusebi LH et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-40.
Farrell B et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354-64.
Fedorak RN et al. Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal reflux disease in Canada: Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010 Jul;24(7):431-4.
Hunt R et al. World Gastroenterology Organisation Global Guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017 Jul;51(6):467-78.
Savarino E et al. The natural history of gastro-esophageal reflux disease: A comprehensive review. Dis Esophagus. 2017 Feb 1;30(2):1-9.
Close

Where are you experiencing discomfort?

Click on the buttons on the body to the left or click from the list below where you are experiencing discomfort.